Biogen (BIIB)
| Company | Ticker | Sector | Industry | Quality | PAR |
|---|---|---|---|---|
| Biogen | BIIB | Healthcare | Biotechnology | 81 | 17.8% |
| Current Price (03/26) | $232.91 | |||
| CAPS Rating (Rate this stock on CAPS) |  |
|||
| Expected Income Statement | ||||
| Current Sales | 13,542.3 | |||
| Sales Growth Forecast | 6.7% | |||
| Net Profit Margin | 35.4% | |||
| Projected Shares Outstanding | 200.00 | |||
| EPS - Five year Forecast | $33.09 | |||
| Average P/E Ratio | 16.0 | |||
| Projected Average Price | $529.45 | |||
| Price Appreciation (Annualized) | 17.8% | |||
| Annual Dividend Yield | 0.0% | |||
| Projected Annual Return | 17.8% | |||
| Quality | ||||
| Financial Strength | 88 | 22.1 | ||
| EPS Stability | 81 | 20.3 | ||
| Industry Sales Growth Rate | 16.5% | 5.0 | ||
| Industry Net Profit Margin | 29.0% | 15.3 | ||
| Calculated Quality Rating | 62.6 | |||
| Fool CAPS | ||||
Total Players
1001
Outperforms
69
Underperforms
All-Stars (246)
236
Outperforms (96%)
10
Underperforms
|
||||
| Fundamental Data Updated: 01/04/2019 | ||||